Updates

CSRXP STATEMENT ON ELI LILLY ANNOUNCEMENT ON PRICE OF INSULIN PRODUCTS

Mar 1, 2023

More Big Pharma Companies Should Also Lower Their Insulin Prices Read More

BIG PHARMA WATCH: NYT REPORT DOCUMENTS NARCOLEPSY DRUG MAKER’S EGREGIOUS EXPLOITATION OF PATENT SYSTEM

Feb 28, 2023

Anti-Competitive Strategy Around Brand Name Narcolepsy Medications Blocked Read More

BIG PHARMA EARNINGS WATCH: ABBVIE AND ASTRAZENECA

Feb 28, 2023

Big Pharma Giants Once Again Top Wall Street Expectations in Final Round of Read More

BIG PHARMA EARNINGS WATCH: MERCK, SANOFI, BRISTOL-MYERS SQUIBB AND ELI LILLY

Feb 21, 2023

Four Big Pharma Giants That Hiked Drug Prices on American Patients in 2022 and Read More

DOSE OF REALITY: BIG PHARMA IS THE CULPRIT BEHIND OUT-OF-CONTROL PRESCRIPTION DRUG PRICES

Feb 16, 2023

Lawmakers Should Focus Attention on Brand Name Drug Companies That Set Prices, Read More

THEY SAID IT! SENATORS HIGHLIGHT URGENCY TO HOLD BIG PHARMA ACCOUNTABLE TO LOWER DRUG PRICES

Feb 13, 2023

Senate Judiciary Committee Advances Bipartisan Legislation Cracking Down on Read More

CSRXP APPLAUDS SENATORS FOR BIPARTISAN ACTION TO HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS PATENT ABUSE

Feb 9, 2023

Senate Judiciary Committee Advances Critical Legislation to Crack Down on Read More

CSRXP APPLAUDS POSITIVE PROGRESS, ENCOURAGES POLICYMAKERS TO ADVANCE ADDITIONAL MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE

Feb 8, 2023

Policies Must Address Big Pharma’s Egregious Practices That Cause High Drug Read More

BIG PHARMA EARNINGS WATCH: PFIZER, AMGEN, GLAXOSMITHKLINE, NOVARTIS AND JOHNSON & JOHNSON

Feb 6, 2023

Brand Name Drug Companies Kick Off Q4 Earnings Calls After More than 600 Price Read More

DOSE OF REALITY: SENATE HEARING PROVIDES OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS PATENT ABUSE

Feb 2, 2023

Critical Legislation Targets Anti-Competitive Practices like Patent Thickets Read More